Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
32.87 USD | +5.02% | +3.88% | +1.10% |
11:38am | Truist Adjusts Price Target on Corcept Therapeutics to $65 From $44, Maintains Buy Rating | MT |
May. 28 | Sector Update: Health Care Stocks Retreat Tuesday Afternoon | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 63% by 2026.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- With an expected P/E ratio at 33.84 and 23.89 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.10% | 3.26B | C- | ||
+42.17% | 748B | C+ | ||
+34.11% | 598B | B | ||
-6.48% | 356B | C+ | ||
+17.72% | 325B | B- | ||
+4.37% | 283B | C+ | ||
+17.02% | 245B | B+ | ||
+9.26% | 211B | B- | ||
-4.21% | 209B | A+ | ||
+2.52% | 166B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CORT Stock
- Ratings Corcept Therapeutics Incorporated